Programmable nanomicelles rewire myeloid immunity for durable control of primary and metastatic breast cancer
Open Access
- 17 March 2026
- journal article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
Immunosuppressive myeloid cells, including immature dendritic cells (DC) and tumor-promoting macrophages, drive tumor progression and immune evasion. Reprogramming these cells into immune effectors remains challenging. Here, we present a programmable nanomicelle platform that reconfigures myeloid immunity to combat both primary and metastatic breast cancer (BC). The nanomicelles co-deliver photosensitizers (IR825), anti-PD-L1 antibodies, and antagomiR-182 with spatiotemporal precision. Upon activation, they induce immunogenic cell death, promoting DC maturation to enhance antigen presentation. Concurrently, miR-182 inhibition repolarizes M2-like macrophages into M1-like phenotypes via the TLR4/MYD88/NF-κB pathway. This dual reprogramming enhances CD8+ T cell infiltration and functionality, driving durable anti-tumor responses. In multiple BC models, the platform suppresses tumor growth, prevents metastasis, and induces long-term immune memory. Its efficacy and immunomodulatory effects were further validated in a patient-derived tumor fragment assay and patient-derived xenograft models, highlighting translational potential. This work offers a clinically relevant strategy to rewire tumor-promoting myeloid cells for cancer immunotherapy.Keywords
This publication has 64 references indexed in Scilit:
- Lung-resident alveolar macrophages regulate the timing of breast cancer metastasisCell, 2024
- Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivationImmunity, 2024
- Mononuclear phagocytes in autoimmune neuroinflammationTrends in Immunology, 2024
- IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancerAnnals of Oncology, 2024
- Functional states of myeloid cells in cancerCancer Cell, 2023
- In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy targetCell, 2021
- Redefining macrophage and neutrophil biology in the metastatic cascadeImmunity, 2021
- Nano-therapeutics for modulating the tumour microenvironment: Design, development, and clinical translationJournal of Controlled Release, 2020
- Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic TargetsCancer Cell, 2019
- Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?European Journal of Medicinal Chemistry, 2019